GLG News by Oncologists who Treat Hematologic Malignancies (US)

APP wants to jump into the void created by Baxter's "allergic" problems related to Chinese suppliers. BUT APP appears to also obtain some of it's product from China and with FDA's scrutiny I would not bet on continued supplies.

Yet another study, although small, report 15 5 incidence of cardiac abnormalities in patients receiving Pfizer's Sutent. The abnormalities persist and are serious in patients with previous history of cardiac disease. Sutent is an efficacious drug, but it has alternative options ( Nexavar and Torisel...

Sutent is associated with cardiac dysfunction!?

As an oncologist we are aware of a drugs efficacy in conditions other than what it has been approved. Avastin in breast cancer; Nexavar and Erbitux in lung cancer, Taxotere in sarcomas. This list would be voluminous and would be a real benefit for patients BUT.......

A recent trial showed that Genentech's Avastin when added to Docotaxel , increased time to progression in patients with recurrent breast cancer. This trial confirms results of a previous study and is reported to have better safety profile. Although survival data are still pending, the efficacy results...

Targeting gynecologic tumors with a "hormone" attached to an effective chemotherapeutic agent.

Very preliminary but if a larger study is confirmatory, and even before in the community, this agent will be used in MS.

"Genentech said Tuesday that a new clinical trial had shown that its best-selling drug Avastin was effective in treating breast cancer, a finding that could increase the chances that the product will be approved for that use."

If there is a production delay in "standard" heparin, it will open the door for LMWH preparations. Which ones? Sanofi-Aventis's Lovenox

Thalidomide post single stem cell transplant is as good as two transplants back to back (tandem.)